Trade

with

NovaBay Pharmaceuticals Inc
(Amex: NBY)
AdChoices
0.8000
+0.0300
+3.90%
After Hours :
-
-
-

Open

0.7600

Previous Close

0.7700

Volume (Avg)

182.27k (311.50k)

Day's Range

0.7600-0.8050

52Wk Range

0.6900-1.80

Market Cap.

40.62M

Dividend Rate ( Yield )

-

Beta

0.42

Shares Outstanding

50.78M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 3.48M

    • Net Income

    • -16.04M

    • Market Cap.

    • 40.62M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -717.43

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.42

    • Forward P/E

    • -3.41

    • Price/Sales

    • 17.30

    • Price/Book Value

    • 4.41

    • Price/Cash flow

    • -2.29

      • EBITDA

      • -15.17M

      • Return on Capital %

      • -110.04

      • Return on Equity %

      • -176.41

      • Return on Assets %

      • -110.04

      • Book Value/Share

      • 0.18

      • Shares Outstanding

      • 50.78M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • -

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -0.27

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -85.50

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -12.35

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 86.53

            • 82.75

            • Pre-Tax Margin

            • -717.28

            • 39.38

            • Net Profit Margin

            • -717.43

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 99.10

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -127.00

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -127.10

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 6.39

              • 2.92

              • Quick Ratio

              • 5.95

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.47

              • 2.21

              • Book Value/Share

              • 0.18

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -2.41

                • 217.39

                • P/E Ratio 5-Year High

                • -8.17

                • 634.30

                • P/E Ratio 5-Year Low

                • -2.02

                • 124.82

                • Price/Sales Ratio

                • 17.30

                • 9.52

                • Price/Book Value

                • 4.41

                • 8.61

                • Price/Cash Flow Ratio

                • -2.29

                • 50.51

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -176.41

                    (-52.70)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -110.04

                    (-34.60)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -176.41

                    (-52.80)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • 2.05

                  • 1.48

                  • Asset Turnover

                  • 0.15

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -15.49M
                  Operating Margin
                  -445.38
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -2.29
                  Ownership

                  Institutional Ownership

                  22.55%

                  Top 10 Institutions

                  27.09%

                  Mutual Fund Ownership

                  2.38%

                  Float

                  86.09%

                  5% / Insider Ownership

                  1.88%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Total Stock Mkt Idx

                  •  

                    521,842

                  • 0.00

                  • 1.03

                  • Vanguard Extended Market Index Fund

                  •  

                    306,020

                  • 7.90

                  • 0.60

                  • Jacob Micro Cap Growth Fund

                  •  

                    166,100

                  • 0.00

                  • 0.33

                  • Bridgeway Ultra Small Company Market

                  •  

                    121,500

                  • 0.00

                  • 0.24

                  • Fidelity Spartan® Extended Mkt Indx Fd

                  •  

                    83,647

                  • 15.98

                  • 0.16

                  • Vanguard Balanced Index Fund

                  •  

                    11,900

                  • 0.00

                  • 0.02

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • China Pioneer Pharma Holdings Ltd

                  •  

                    7,113,812

                  • +236.54%

                  • 18.06

                  • Vanguard Group, Inc.

                  •  

                    790,383

                  • +6.40%

                  • 1.56

                  • Glenmede Trust Co NA

                  •  

                    300,000

                  • 0.00%

                  • 0.59

                  • Jacob Asset Management Of New York LLC

                  •  

                    166,100

                  • 0.00%

                  • 0.33

                  • Orbitronix LP

                  •  

                    150,000

                  • +87.11%

                  • 0.30

                  • Garrison Bradford & Associates Inc

                  •  

                    128,000

                  • -7.25%

                  • 0.25

                  • Bridgeway Capital Management, Inc

                  •  

                    121,500

                  • 0.00%

                  • 0.24

                  • California Public Employees Retrmnt Sys

                  •  

                    103,100

                  • 0.00%

                  • 0.20

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Core

                  NovaBay Pharmaceuticals, Inc., was incorporated under the laws of the State of California on January 19, 2000, as NovaCal Pharmaceuticals, Inc., and subsequently changed its name to NovaBay Pharmaceuticals, Inc. The Company is a cli...morenical-stage biopharmaceutical company focused on addressing the unmet therapeutic needs of the global, topical anti-infective market with its two distinct categories of products, Aganocides and NeutroPhase. The Company is focusing its Aganocide compounds into three large therapeutic markets: Urology – Statistically-significant and clinically-meaningful results from a Phase 2 clinical study of Auriclosene Irrigation Solution to reduce urinary catheter blockage and encrustation, Ophthalmology - NovaBay is developing an eye drop formulation of auriclosene (NVC-422) for trea...moreting adenoviral conjunctivitis, for which there is currently no FDA-approved treatment, Dermatology - Partnered with Galderma, a dermatology company, the Company is developing a gel formulation of auriclosene (NVC-422) for treating impetigo, a contagious skin infection. The Company has also developed NeutroPhase, a distinct class of molecule from the Aganocides. NeutroPhase is an FDA 510(k)-cleared Advanced Skin and Wound Cleanser. It has developed variations of the NeutroPhase product such as i-Lid Cleanser and CelleRx. The competitors for its Aganocides and for NeutroPhase include large and small pharmaceutical and medical device companies, such as Pfizer, Inc., Johnson & Johnson, Abbott Grp. Plc., GlaxoSmithKline Plc, Sanofi-Aventis SA, Novartis AG, Smith & Nephew Plc, C.R. Bard, Molnlycke, Lohman and Roucher, Johnson and Johnson, 3M, Puricore and Oculus Innovative Sciences. The Company’s Aganocide product candidate, auriclosene (NVC-422), as well as many of the product candidates they expect to develop in the future. The testing, manufacturing, labeling, advertising, promotion, distribution, export and marketing of its product candidates are subject to extensive regulation by the FDA, state agencies and comparable regulatory authorities in other countries.lessless

                  Key People

                  Dr. Ramin Najafi,PhD

                  CEO/Chairman of the Board/Director/President

                  Thomas J. Paulson

                  CFO/Chief Accounting Officer/Secretary/Treasurer

                  Mark M. Sieczkarek

                  Director

                  Dr. Massimo Radaelli,PhD

                  Director

                  Mr. Paul E. Freiman

                  Director

                  • NovaBay Pharmaceuticals Inc

                  • 5980 Horton street

                  • Emeryville, CA 94608

                  • USA.Map

                  • Phone: +1 510 899-8800

                  • Fax: +1 510 225-0371

                  • novabaypharma.com

                  Incorporated

                  2000

                  Employees

                  34

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: